These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

494 related articles for article (PubMed ID: 22938926)

  • 1. Changing patterns of anemia management in US hemodialysis patients.
    Freburger JK; Ng LJ; Bradbury BD; Kshirsagar AV; Brookhart MA
    Am J Med; 2012 Sep; 125(9):906-14.e9. PubMed ID: 22938926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Triumph and tragedy: anemia management in chronic kidney disease.
    Novak JE; Szczech LA
    Curr Opin Nephrol Hypertens; 2008 Nov; 17(6):580-8. PubMed ID: 18941350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of facility-level hemoglobin concentration on dialysis patient risk of transfusion.
    Collins AJ; Monda KL; Molony JT; Li S; Gilbertson DT; Bradbury BD
    Am J Kidney Dis; 2014 Jun; 63(6):997-1006. PubMed ID: 24315770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The influence of need-based, continuous, low-dose iron replacement on hemoglobin levels in hemodialysis patients treated with erythropoiesis-stimulating agents.
    Malovrh M; Hojs N; Premru V
    Artif Organs; 2011 Jan; 35(1):63-8. PubMed ID: 20618233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hemodialysis-associated hemosiderosis in the era of erythropoiesis-stimulating agents: a MRI study.
    Rostoker G; Griuncelli M; Loridon C; Couprie R; Benmaadi A; Bounhiol C; Roy M; Machado G; Janklewicz P; Drahi G; Dahan H; Cohen Y
    Am J Med; 2012 Oct; 125(10):991-999.e1. PubMed ID: 22998881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of proactive iron and erythropoiesis-stimulating agent protocol implementation on achieving clinical guideline targets for anaemia in a satellite haemodialysis patient cohort.
    Yong K; Kairaitis L
    Nephrology (Carlton); 2010 Apr; 15(3):288-93. PubMed ID: 20470296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of IV iron compared to oral iron for increment of haemoglobin level in anemic chronic kidney disease patients on erythropoietin therapy.
    Adhikary L; Acharya S
    JNMA J Nepal Med Assoc; 2011; 51(183):133-6. PubMed ID: 22922860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of intravenous iron sucrose in peritoneal dialysis patients who receive erythropoiesis-stimulating agents for anemia: a randomized, controlled trial.
    Singh H; Reed J; Noble S; Cangiano JL; Van Wyck DB;
    Clin J Am Soc Nephrol; 2006 May; 1(3):475-82. PubMed ID: 17699248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Current issues in erythropoietin therapy of renal anemia].
    Zakar G
    Lege Artis Med; 2007 Oct; 17(10):667-73. PubMed ID: 19227596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perihospitalization patterns of hemoglobin levels and erythropoiesis-stimulating agent doses in US hemodialysis patients, 1998-2009.
    Foley RN; Solid CA; Lamb K
    Hemodial Int; 2014 Jan; 18(1):24-31. PubMed ID: 24131588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients.
    Regidor DL; Kopple JD; Kovesdy CP; Kilpatrick RD; McAllister CJ; Aronovitz J; Greenland S; Kalantar-Zadeh K
    J Am Soc Nephrol; 2006 Apr; 17(4):1181-91. PubMed ID: 16565261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomedical system dynamics to improve anemia control with darbepoetin alfa in long-term hemodialysis patients.
    McCarthy JT; Hocum CL; Albright RC; Rogers J; Gallaher EJ; Steensma DP; Gudgell SF; Bergstralh EJ; Dillon JC; Hickson LJ; Williams AW; Dingli D
    Mayo Clin Proc; 2014 Jan; 89(1):87-94. PubMed ID: 24388026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comprehensive vision for intravenous iron therapy.
    Coyne DW
    Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S14-20. PubMed ID: 19010257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Iron isomaltoside 1000: a new intravenous iron for treating iron deficiency in chronic kidney disease.
    Wikström B; Bhandari S; Barany P; Kalra PA; Ladefoged S; Wilske J; Thomsen LL
    J Nephrol; 2011; 24(5):589-96. PubMed ID: 21240875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The new label for erythropoiesis stimulating agents: the FDA'S sentence.
    Fishbane S; Jhaveri KD
    Semin Dial; 2012 May; 25(3):263-6. PubMed ID: 22515844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
    Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
    Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of two recombinant erythropoietin formulations in patients with anemia due to end-stage renal disease on hemodialysis: a parallel, randomized, double blind study.
    Pérez-Oliva JF; Casanova-González M; García-García I; Porrero-Martín PJ; Valenzuela-Silva CM; Hernández-Montero T; Lagarde-Ampudia M; Casanova-Kutsareva Y; Avila-Albuerne Y; Vargas-Batista A; Bobillo-López H; Herrera-Valdés R; López-Saura PA;
    BMC Nephrol; 2005 May; 6():5. PubMed ID: 15910687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. It's time to compare anemia management strategies in hemodialysis.
    Coyne DW
    Clin J Am Soc Nephrol; 2010 Apr; 5(4):740-2. PubMed ID: 20299363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of mean weekly epoetin alfa dose with mortality risk in a retrospective cohort study of Medicare hemodialysis patients.
    Weinhandl ED; Gilbertson DT; Collins AJ
    Am J Nephrol; 2011; 34(4):298-308. PubMed ID: 21829009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.